Pipeline news
-
11 March 2020
Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia , has acquired an exclusive license for the commercialization and development of XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland China , Hong Kong , Macau and Taiwan ) and South Korea .
-
Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer
11 March 2020
Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer. He will continue to serve on the Board of Directors. This appointment was effective March 1, 2020.
-
03 March 2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2019 . In addition, the Company provided a clinical and business update. As of December 31, 2019 , Syndax had $59.8 million in cash, cash equivalents and short-term investments.
-
25 February 2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it has reached the 100 patient enrollment target for the Marigold Study. The Marigold Study is a pivotal Phase 3 study evaluating oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder (CDD), a rare refractory form of pediatric epilepsy with no currently approved treatments. The Company will continue enrollment through the end of the month to capture the remaining few patients in the screening phase. Marinus is on-track to report top-line results in the third quarter of 2020.
-
31 January 2020
Syndax Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with five leading life sciences investors, including Biotechnology Value Fund, L.P. , Boxer Capital and AI Life Sciences Investments LLC , an affiliate of Access Industries Inc. , for the purchase of common stock at $8.00 per share, representing a premium of 20% to the share price as of market close on Thursday, January 30, 2020 . Syndax anticipates aggregate gross proceeds from the offering will be approximately $35.0 million.
-
30 January 2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML).
-
28 January 2020
Bausch Health Companies Inc. (NYSE/TSX: BHC) (" Bausch Health ") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical , Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology , has published results from the randomized, controlled, double-masked Phase 3 clinical trial (PEACHTREE study) of XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension), an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.1
-
13 January 2020
binx health today announced the launch of its pre-order program for the world’s first FDA-cleared, rapid molecular point-of-care instrument, which provides diagnosis in about 30 minutes to enable single visit test and treatment for chlamydia (CT) and gonorrhea (NG) in women. CT and NG are two of the most tested-for sexually transmitted infections (STIs) globally. binx received FDA 510(k) clearance in August 2019 for its female offering, and is submitting a 510(k) filing for its male urine offering in Q1 2020.
-
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
10 January 2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a strategic outlook for 2020 outlining key priorities for its broad pipeline.
-
13 December 2019
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 32,200,000 shares of common stock at a public offering price of $1.25 per share, including the exercise in full by the underwriters of their option to purchase up to 4,200,000 additional shares of common stock. The offering included participation from new and existing investors, and together with the concurrent private placement raised gross proceeds of approximately $70 million, before deducting underwriting discounts and commissions, placement agent fees and estimated offering expenses payable by the Company.
